Indofarma Tbk. vs Trimegah Bangun Persada Tbk. — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Trimegah Bangun Persada Tbk. trades at Rp940 (market cap 60.26T, 66.68M 24h volume). The key difference: Trimegah Bangun Persada Tbk. is far larger — about 154.3× Indofarma Tbk.'s market cap. Which is the better fit depends on your goals.
| INAF | NCKL | |
|---|---|---|
Market Cap | 390.51B | 60.26T |
Volume | — | 66.68M |
Lot | — | 666.76K |
Turnover | — | 62.63B |
Average Price | — | 939.35 |
Value | — | 62.63B |
Indicative Equilibrium Price | — | 940 |
Indicative Equilibrium Volume | — | 13.51K |
Trailing returns across standard periods
Latest headlines on both assets
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Read more on INAF →PT Trimegah Bangun Persada Tbk. (the Company) was established in Indonesia based on Notarial Deed of Erna Priyono, S.H., No. 03 dated September 6, 2004.
Read more on NCKL →